PsiOxus Therapeutics is a clinical-stage oncology company that is dedicated to improving the lives of individuals living with cancer through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. To accomplish this goal, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. The company was established in 2010 after the merger of two companies, Myotec Therapeutics and Hybrid BioSystems.
Over the last several years, we have undergone an incredible transformation as a company, and our new name reinforces this evolution and our focused commitment to oncology drug development. The $30 million financing will enable the continued advancement of our clinical pipeline of T-SIGn® therapeutics and further establishes our US footprint.
Howard Davis, Ph.D., CEO of Akamis Bio
As the new year begins, PsiOxus Therapeutics has made the exciting announcement of a new name and a $30 million convertible note financing. The company’s new name Akamis Bio is inspired by Akamas, a warrior in Greek mythology known for being part of the Trojan horse story. In addition to the company’s new name and visual identity, Akamis Bio has taken a significant step to solidify its online presence by securing the exact match domain, AkamisBio.com. This domain will serve as the primary online home for the company, allowing customers and stakeholders to easily access information about Akamis Bio and its products and services.
While the cost of a premium domain name may be intimidating, the potential loss in terms of brand recognition and revenue is much greater. Contact us to learn more about premium domains and how they can help your business thrive.